Markets:

Overview

News

Currencies

International

Treasuries

Eli Lilly (NY:LLY)

1,012.08 +23.99 (+2.43%)

Streaming Delayed Price Updated: 11:07 AM EDT, May 19, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2

...

12 13 14 15 16 17 18 19 20

...

99 100 Next >

Eli Lilly Announces New Version Of Zepbound With A Month’s Worth Of Doses In KwikPen — How Much Will It Cost? ↗

February 23, 2026

The new Zepbound KwikPen can be purchased by cash-paying customers through LillyDirect, Eli Lilly’s direct-to-customer website.

Via Stocktwits

Wondering what's happening in today's S&P500 pre-market session? ↗

February 23, 2026

Via Chartmill

Novo Nordisk Dives As Next-Gen Obesity Drug Fails To Match Eli Lilly's Zepbound ↗

February 23, 2026

Novo's next-gen drug CagriSema didn't match weight loss from Eli Lilly's Zepbound.

Via Investor's Business Daily

1 Reason I'm Seriously Considering Novo Nordisk as a Buy‑and‑Never‑Sell Obesity Stock ↗

February 23, 2026

Novo Nordisk investors get a second bite at the Ozempic apple.

Via The Motley Fool

3 Reasons Viking Therapeutics Stock Could 10X if Its Obesity Pipeline Succeeds ↗

February 23, 2026

Viking stock has plenty of room to run.

Via The Motley Fool

Corcept (CORT) Q4 Earnings: What To Expect

February 22, 2026

Biopharma company Corcept Therapeutics (NASDAQ:CORT) will be announcing earnings results this Tuesday afternoon. Here’s what to expect.

Via StockStory

Topics Artificial Intelligence World Trade

Jazz Pharmaceuticals Earnings: What To Look For From JAZZ

February 22, 2026

Biopharma company Jazz Pharmaceuticals (NASDAQ:JAZZ) will be announcing earnings results this Tuesday after market close. Here’s what you need to know.

Via StockStory

Topics Artificial Intelligence Government World Trade

Supernus Pharmaceuticals (SUPN) To Report Earnings Tomorrow: Here Is What To Expect

February 22, 2026

Specialty pharmaceutical company Supernus Pharmaceuticals (NASDAQ:SUPN) will be announcing earnings results this Tuesday after market hours. Here’s what investors should know.

Via StockStory

Topics Artificial Intelligence

What To Expect From Elanco’s (ELAN) Q4 Earnings

February 22, 2026

Animal health company Elanco (NYSE:ELAN) will be reporting earnings this Tuesday before market open. Here’s what you need to know.

Via StockStory

Could Vertex Stock Help Turn $100,000 Into $1 Million by 2036? ↗

February 22, 2026

Even a great stock has a ceiling.

Via The Motley Fool

Topics Intellectual Property

2 Unstoppable Dividend Stocks to Buy Right Now for Less Than $200 ↗

February 22, 2026

These two healthcare stocks are likely headed higher from their current prices.

Via The Motley Fool

3 Brilliant Growth Stock ETFs to Buy Now and Hold for the Long Term ↗

February 21, 2026

Growth stock ETFs offer a catch-all way to buy the dip in top stocks.

Via The Motley Fool

Topics Artificial Intelligence ETFs

The Stock Market Just Did This for the First Time in Nearly a Year. History is Strikingly Clear About What Happens Next. ↗

February 21, 2026

Market gains have left some stocks trading at expensive levels.

Via The Motley Fool

Topics Artificial Intelligence Economy

Novo Nordisk Stock Investors Just Got Great News From Eli Lilly ↗

February 20, 2026

But it's good news for Eli Lilly, too.

Via The Motley Fool

Is Pfizer Stock an Underrated Healthcare Investment Play? ↗

February 20, 2026

Pfizer is playing catch-up in the GLP-1 drug space, but the drugmaker has a long history of success.

Via The Motley Fool

Topics Intellectual Property

Forget Ozempic: This High‑Flying Device Maker Can Thrive No Matter Which Weight Loss Drug Wins ↗

February 20, 2026

Wall Street is overly focused on GLP-1 drugs even as this medical device maker continues to thrive.

Via The Motley Fool

Topics Artificial Intelligence

Eli Lilly Breaks New Ground In Crohn's Disease Treatment ↗

February 20, 2026

Eli Lilly (LLY) reports landmark Phase 3 data for Omvoh, showing over 90% of Crohn's disease patients achieved 3-year steroid-free remission.

Via Benzinga

Is Pfizer Stock the Only Big Pharma Name I'd Buy and Hold Through Any Market Crash? ↗

February 20, 2026

New products are already generating growth.

Via The Motley Fool

Topics Intellectual Property

ORBIMED Advisors Trims $125 Million Terns Stake After a Breakout Year, According to SEC Filing ↗

February 20, 2026

Terns Pharmaceuticals has delivered a significant rally over the past year, lifting expectations around its clinical pipeline. The latest filing shifts attention to upcoming data and the company’s...

Via The Motley Fool

Topics Regulatory Compliance

3 Market-Beating Stocks to Consider Right Now

February 19, 2026

Companies that consistently increase their sales, margins, or returns on capital are usually rewarded with the best returns, and those that can do all three for years on end are almost always the...

Via StockStory

2 Innovative Biotech Stocks That May Climb 58% and 200%, According to Wall Street ↗

February 19, 2026

These biotech companies have catalysts ahead.

Via The Motley Fool

Warning: This Skyrocketing Stock Has a Hidden Risk ↗

February 19, 2026

Eli Lilly is leading the pack in the GLP-1 weight-loss drug market, but this good news won't last forever.

Via The Motley Fool

Topics Intellectual Property

Prediction: Eli Lilly Stock Could Surge 45% This Year ↗

February 19, 2026

Eli Lilly just delivered explosive growth, and analysts see up to 45% upside, but is this pharma giant still a buy at its current price?

Via The Motley Fool

Overlooked and Undervalued: Why Novo Nordisk Stock Deserves Attention ↗

February 19, 2026

Novo Nordisk looks attractively priced even though 2026 is likely to be a tough year.

Via The Motley Fool

Is Viking Therapeutics Stock Really Going to $125? ↗

February 19, 2026

Never say never. There's certainly a mathematical path to that level, if the company navigates it correctly.

Via The Motley Fool

3 Stocks to Buy and Hold for 2026 and Beyond ↗

February 19, 2026

Any of these three pharmaceutical titans could move the needle in your portfolio.

Via The Motley Fool

Topics Economy Intellectual Property

Pfizer’s BRAFTOVI BREAKWATER Trial Delivers Landmark Survival Gains in Colorectal Cancer

February 19, 2026

NEW YORK — Pfizer Inc. (NYSE: PFE) has announced breakthrough results from its Phase 3 BREAKWATER clinical trial, demonstrating that its BRAFTOVI (encorafenib) regimen significantly improves both...

Via MarketMinute

Forget Ozempic: This Obesity‑Drug Giant Is Grabbing the Biggest Slice of the GLP‑1 Gold Rush ↗

February 19, 2026

Ozempic's rival is generating blockbuster revenue and gaining market share.

Via The Motley Fool

Nasdaq, S&P 500 Futures Edge Higher, Trump Speech In Focus: Why WMT, META, IBRX, MSFT, EBAY Are On Traders' Radar Today ↗

February 19, 2026

Data from Stocktwits indicated retail sentiment towards SPY and QQQ cooled to neutral.

Via Stocktwits

Topics ETFs Economy Government

2 High-Flying Stocks on Our Buy List and 1 Facing Challenges

February 18, 2026

Expensive stocks typically earn their valuations through superior growth rates that other companies simply can’t match. The flip side though is that these lofty expectations make them particularly...

Via StockStory

Topics Firearms

< Previous 1 2

...

12 13 14 15 16 17 18 19 20

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Eli Lilly (NY:LLY)

All News about Eli Lilly

Starting at $3.75/week.

Subscribe Today